Cargando…
Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
BACKGROUND: Modern drugs could sometimes be a good solution even to problematic patients. The cutaneous and systemic forms of the CD30 positive anaplastic large T-cell lymphoma could often be described as a suitable target for therapy with Brentuximab vedotin. CASE REPORT: We present the first case...
Autores principales: | Popova, Tanya Naskova, Radinov, Atanass, Stavrov, Konstantin, Temelkova, Ivanka, Terziev, Ivan, Lozev, Ilia, Lukanova, Detelina, Mangarov, Hristo, Wollina, Uwe, Tchernev, Georgi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Republic of Macedonia
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062288/ https://www.ncbi.nlm.nih.gov/pubmed/30087736 http://dx.doi.org/10.3889/oamjms.2018.289 |
Ejemplares similares
-
Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
por: Cranmer, Holly, et al.
Publicado: (2022) -
The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL
por: Allchin, Rebecca L., et al.
Publicado: (2020) -
Pretibial Located Stewart-Treves Syndrome: Uncommon Presentation in a Bulgarian Patient!
por: Tchernev, Georgi, et al.
Publicado: (2018) -
Nevus Blue as a Sporadic Finding in a Patient with a Blue Toe?
por: Temelkova, Ivanka, et al.
Publicado: (2018) -
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK(+) ALCL: results of COG trial ANHL12P1
por: Lowe, Eric J., et al.
Publicado: (2021)